Jazz Pharmaceuticals plc (JAZZ) and AbCellera Biologics Inc. (ABCL) have entered into a research collaboration and license agreement to discover and develop next-generation T-cell engaging (TCE) multispecific antibodies for the treatment of gastrointestinal (GI) cancers and other solid tumors.
The partnership combines Jazz's oncology expertise with AbCellera's antibody discovery platform to identify and optimize therapeutic candidates aimed at improving immune-based cancer treatments.
Collaboration Overview
Under the agreement, AbCellera will lead discovery and early-stage research for two initial programs, with a third program expected to begin within 12 months. Jazz will hold exclusive, worldwide right to develop and commercialize any resulting antibodies once it exercises its option for each program.
AbCellera will receive $56 million in upfront payments for the first two programs and an additional $28 million upon initiation of the third. If Jazz advances the programs into development, AbCellera could earn up to $792 million per program in potential milestone payments, plus tiered royalties on future sales ranging from mid-single to low double digits.
The companies may also agree to launch two additional discovery programs and collaborate on investigational new drug-enabling studies and clinical supply manufacturing.
Strategic Significance
"This collaboration aligns with Jaaz's oncology strategy and expands our focus on GI cancers," said Josh Allen, Ph.D., Chief Scientific Officer, Oncology at Jazz Pharmaceuticals, noting that the partnership aims to advance potential best-in-class antibody therapies into clinical development.
AbCellera CEO Carl Hansen, Ph.D., added that the company's T-cell engager platform, which integrates discovery through clinical manufacturing, will help deliver novel multispecific antibodies capable of driving targeted immune activation against difficult-to-treat cancers.
JAZZ has traded between $105.00 and $243.32 over the past year. The stock closed Tuesday's trading at $226.88, down 1.61%. In pre-market trading the stock is at $230.00, up 1.38%.
For comments and feedback contact: editorial@rttnews.com
Business News
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.